Compare CALC & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALC | FCUV |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.3M |
| IPO Year | 2020 | 2013 |
| Metric | CALC | FCUV |
|---|---|---|
| Price | $1.08 | $3.52 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | ★ 56.0K | 28.7K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,023.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $0.13 |
| 52 Week High | $72.00 | $23.00 |
| Indicator | CALC | FCUV |
|---|---|---|
| Relative Strength Index (RSI) | 23.53 | 38.23 |
| Support Level | $0.44 | $0.15 |
| Resistance Level | $2.31 | $7.40 |
| Average True Range (ATR) | 0.12 | 0.42 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 0.00 | 14.49 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Focus Universal Inc focuses on commercializing universal smart technology and financial reporting software. It plans to utilize its universal smart technology for smart meters and automation systems, which will be incorporated into IoT devices. The company has developed the five proprietary platform technologies: device on a chip; universal smart instrumentation platform (USIP); 5G ultra-narrowband technology; ultra-narrowband power line communication (PLC) technology; and its financial reporting software. The company consists of two segments: LED and IoT Installation Services, and SEC Financial Software segment. It derives the majority of the revenue from LED and IoT Installation Services segment which handles LED and IoT installation and management business.